This study highlights how the unique microRNA expression signature of patients with KMT2A::AFF1+ BCP-ALL can be used to uncover novel therapeutic avenues and accelerate drug repurposing. This evidence concerns the gene AFF1 and acute lymphoblastic leukemia.